The clinical efficacy of vitamin D in children with primary low bone mass
- PMID: 21489355
The clinical efficacy of vitamin D in children with primary low bone mass
Abstract
Introduction: Vitamin D supplementation in prevention and treatment of osteoporosis is a widely accepted standard, but the latest studies show the necessity of increasing the intake of this vitamin to keep its concentration on higher levels - above 30 ng/ml. The best index describing the body vitamin D supply is hepatic metabolite of vitamin D (25OHD) concentration in the serum. There are few data on efficacy of this vitamin intake in children with low bone mass. AIM OF THE STUDY was to find out if vitamin D supplementation causes a significant increase in the hepatic metabolite concentrations and how it affects the clinical course of the disease and the results of densitometric tests in children with primary low bone mass.
Material and methods: Seventy six children aged 6 to 18.5 years (35 girls and 41 boys) with primary osteoporosis or low bone mass diagnosed based on clinical and densitometric signs were included in the study. In all children, the concentrations of 25OD and PTH were measured and densitometric evaluations were taken twice, before and after 1 year of vitamin D intake. According to literature data, 30 ng/ml was adopted as the lower limit of normal 25OHD levels in children with osteoporosis and low bone mass.
Results: Vitamin D supplementation for 12 months of osteoporosis and low bone mass therapy in children caused a statistically significant increase in concentrations of the hepatic metabolite of vitamin D and a significant reduction in serum PTH levels. The changes in 25OHD levels depended on the vitamin D dose used (658 IU/day), and only this amount allowed to achieve an improvement in the densitometric parameters, in particular the increase in bone mineral density (BMD) in the lumbar spine.
Conclusions: 1. Based on the performed study in children with idiopathic reduction of bone mineral density the normalisation of the calcitropic hormones and improvement in the densitometric parameters assessing bone mineral density is necessary. 2. A detailed statistical analysis has shown that the increase in both vitamin D metabolites and bone mineral density is caused by vitamin D supplementation at a dose of 685 IU/day; this is an important practical aspect of this study.
Similar articles
-
The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.BMC Musculoskelet Disord. 2007 Jan 10;8:3. doi: 10.1186/1471-2474-8-3. BMC Musculoskelet Disord. 2007. PMID: 17214897 Free PMC article. Clinical Trial.
-
Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: effect of supplementation with vitamin D and calcium.Pediatr Pulmonol. 2008 Aug;43(8):772-80. doi: 10.1002/ppul.20863. Pediatr Pulmonol. 2008. PMID: 18615666 Clinical Trial.
-
Bone mineral status, bone turnover markers and vitamin D status in children with congenital adrenal hyperplasia.Minerva Endocrinol. 2012 Sep;37(3):275-82. Minerva Endocrinol. 2012. PMID: 22766894
-
Reducing fracture risk with calcium and vitamin D.Clin Endocrinol (Oxf). 2010 Sep;73(3):277-85. doi: 10.1111/j.1365-2265.2009.03701.x. Clin Endocrinol (Oxf). 2010. PMID: 20796001 Review.
-
Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment.Proc Nutr Soc. 2008 May;67(2):163-76. doi: 10.1017/S0029665108007003. Proc Nutr Soc. 2008. PMID: 18412990 Review.
Cited by
-
Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.Curr Osteoporos Rep. 2014 Sep;12(3):289-99. doi: 10.1007/s11914-014-0228-x. Curr Osteoporos Rep. 2014. PMID: 25001898 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials